- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01223768
Acetyl-L-Carnitine In Severe Hepatic Encephalopathy
October 18, 2010 updated by: University of Catania
To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Catania, Italy, 95126
- Cannizzaro Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with severe hepatic encephalopathy (grade 3 of the West Haven grading scale) with hepatic cirrhosis
Exclusion Criteria:
- Patients with a history of recent alcohol abuse, patients using psychotropic drugs (e.g., antipsychotics, interferon, benzodiazepines, anti-epileptics, sedatives and antidepressants)
- Other exclusion criteria were the following: major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis; acute superimposed liver injury;patients with metabolic disorders such as diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage renal disease; any additional precipitating factors such as high protein intake (additional high-protein meals), constipation; illiteracy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
twice per day
|
Experimental: Acetyl-L-carnitine
|
2g per day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Study Completion
December 1, 2005
Study Registration Dates
First Submitted
October 18, 2010
First Submitted That Met QC Criteria
October 18, 2010
First Posted (Estimate)
October 19, 2010
Study Record Updates
Last Update Posted (Estimate)
October 19, 2010
Last Update Submitted That Met QC Criteria
October 18, 2010
Last Verified
December 1, 2000
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Failure
- Hepatic Insufficiency
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Brain Diseases, Metabolic
- Hepatic Encephalopathy
- Brain Diseases
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Vitamin B Complex
- Nootropic Agents
- Acetylcarnitine
Other Study ID Numbers
- 8-12-00 C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acetyl-l-Carnitine
-
Dong-A ST Co., Ltd.CompletedAlzheimer DiseaseKorea, Republic of
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Rhode Island Hospital and other collaboratorsNot yet recruitingAlcohol Use DisorderUnited States
-
Ain Shams UniversityCompleted
-
Khyber Medical University PeshawarCompleted
-
Vanderbilt University Medical CenterCompletedLung Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Carnitine Nutritional DeficiencyUnited States
-
Vanderbilt UniversityCompleted
-
University of AlbertaCompletedCarpal Tunnel Syndrome | Compression NeuropathyCanada
-
University of South FloridaUnknownFriedreich's AtaxiaUnited States